Biomea Fusion Q2 net loss $37.3M; FDA clinical hold on diabetes trials; topline readouts on track for Q4

Biomea Fusion, Inc.

2024-Q2 EPS reported -$2.12

Net loss $37.3M in Q2 vs $24.9M YoY; cash $113.7M, down from $177.2M end of 2023.
FDA imposed full clinical hold on BMF-219 diabetes trials due to hepatotoxicity concerns.
Topline data from Phase 2b (type 2, ~195 pts) and Phase 2a (type 1, ~20 pts) still expected Q4 2024.
Third obesity program (oral GLP-1R agonist) to be announced Q3 2024.
Two COVALENT-101 cohorts (CLL, DLBCL) discontinued due to insufficient enrollment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.